Overview

A Study in Subjects With Recurrent Malignant Glioma

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Bevacizumab
Lenvatinib